Search for a trial | Research with human participants

1 results

A Phase 3, Multicenter, Open-Label 156-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants with Chronic or Episodic Migraine

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2023-507096-21-00 check the CTIS register for the current data. To evaluate the safety and tolerability of treatment with atogepant 60 mg once daily when administered over 156 weeks for the prevention…